Cellectar Biosciences} stock has undergone multiple analysts rating changes in the recent past. Cellectar Biosciences Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.
View More Cellectar Biosciences (NASDAQ:CLRB) Downgraded by Zacks Investment Research to Hold
Cellectar Biosciences} stock has undergone multiple analysts rating changes in the recent past. Cellectar Biosciences Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.
View More Cellectar Biosciences (CLRB) Upgraded by Zacks Investment Research to Buy
Earnings results for Cellectar Biosciences , Analyst Opinion on Cellectar Biosciences , Earnings and Valuation of (NASDAQ:CLRB), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,
View More Earnings and Growth Analysis : Cellectar Biosciences (NASDAQ:CLRB)
